Navigation Links
FDA Provides Cornerstone Pharmaceuticals Approval to Initiate Pivotal Study for CPI-613, its Metabolism-Directed Anticancer Compound
Date:3/23/2017

CRANBURY, N.J., March 23, 2017 /PRNewswire/ -- Cornerstone Pharmaceuticals, Inc., a clinical-stage, oncology-focused pharmaceutical company, announced a major milestone today.  Following successful End-of-Phase I (EOP1) Type B meetings with the U.S. Food and Drug Administration (FDA), the Company has been given a clear clinical and regulatory path forward to conduct pivotal trials of its lead compound, CPI-613, in patients with acute myeloid leukemia (AML) and pancreatic cancer.

CPI-613 is Cornerstone Pharmaceuticals' first-in-class anticancer compound from its proprietary Altered Energy Metabolism Directed (AEMD) platform. The drug is designed to disrupt the altered energy production pathways in cancer cells by targeting the mitochondrial tricarboxylic acid (TCA) cycle, an indispensable process essential to cell multiplication and survival. The FDA has designated CPI-613 an orphan drug for the treatment of acute myeloid leukemia (AML), pancreatic cancer and myelodysplastic syndromes (MDS).

"Our productive dialogue with the FDA has cleared a path forward for initiating pivotal trials of CPI-613, which may be sufficient to support our proposed indications for the treatment of AML and pancreatic cancer," said Sanjeev Luther, Chief Operating Officer, Cornerstone Pharmaceuticals. "The FDA has provided valuable feedback to inform a design that will enhance the robustness of our trials. This would allow the Agency to assess them as registrational trials. We are confident in our ability to meet the FDA's requirements for the trials, and look forward to continued interaction with the FDA as the CPI-613 clinical development program advances."

During the EOP1 Type B meetings with the FDA, Cornerstone Pharmaceuticals presented updated results from Phase I trials of CPI-613 in patients with AML and pancreatic cancer.

"We believe the Phase II trial in AML can potentially lead to approval for treatment of a disease that historically has been extremely difficult to treat," said Jorge Cortes, M.D., lead investigator of the AML trials and Deputy Chair and Professor of Medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center.

"We are encouraged that the FDA has granted us the opportunity to continue clinical trials in pancreatic cancer, a disease with large unmet clinical need, and are optimistic that we will continue to see positive results in advanced pancreatic cancer patients," commented Philip A. Philip, M.D., Ph.D., F.R.C.P., lead investigator of the pancreatic cancer trials and Professor of Oncology and Pharmacology, Leader, GI and Neuroendocrine Oncology, and Vice President of Medical Affairs at Karmanos Cancer Center, Wayne State University.

About Cornerstone Pharmaceuticals, Inc.

Cornerstone Pharmaceuticals, Inc. is a clinical-stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Cornerstone's primary objective is to develop highly selective and effective agents with minimal toxic effects on normal cells and tissues. Cornerstone's first-in-class clinical lead compound, CPI-613 is being evaluated in multiple Phase I, I/II, and II clinical studies. The U.S. Food and Drug Administration (FDA) has designated CPI-613 an orphan drug for the treatment of acute myeloid leukemia (AML), pancreatic cancer and myelodysplastic syndromes (MDS). The company's investors include IDT Corporation (NYSE: IDT). For more information, visit www.cornerstonepharma.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements relate to future events or the company's future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward-looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.

Contact:
Jacob Jonas
Public Relations, Cornerstone Pharmaceuticals, Inc.
jacob@cornerstonepharma.com  

Kara Golub
JFK Communications, Inc.
609-456-0822
kgolub@jfkhealth.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/fda-provides-cornerstone-pharmaceuticals-approval-to-initiate-pivotal-study-for-cpi-613-its-metabolism-directed-anticancer-compound-300428286.html


'/>"/>
SOURCE Cornerstone Pharmaceuticals, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Update - Ampio Pharmaceuticals Provides Corporate Update
2. PTC Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
3. Marapharm Ventures Inc. "Marapharm" Provides Construction Updates for 13.6 Acres of Industrial Land and Buildings Located in Washington State and 7 Acres in Nevada
4. Pulmatrix Reports 2016 Financial Results; Provides 2017 Outlook on Pulmonary Disease Pipeline
5. ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
6. Mirati Therapeutics Reports Financial Results And Provides Business Update For The Fourth Quarter And Full Year 2016
7. Rigel Announces Fourth Quarter 2016 and Year End 2016 Financial Results and Provides Company Update
8. New convenient air-sampling device provides first-ever unique home allergen profiles
9. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2016 Fourth Quarter And Full Year Financial Results
10. Veracyte Announces Fourth Quarter and Full-Year 2016 Financial Results, Provides 2017 Financial Outlook
11. Halyard Health, Inc. Announces Fourth Quarter and Full-Year 2016 Results, Provides 2017 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2019)... LITTLE ROCK, Ark. (PRWEB) , ... October 11, ... ... National Case Management Week starting October 13, 2019, to recognize the dedication, compassion ... Case management is a collaborative process, providing a unique and vital link between ...
(Date:10/11/2019)... ... October 11, 2019 , ... On Sep. 8, 2019, ... held the grand opening for Long Island’s first-of-a-kind boutique CBD storefront. Located at ... lineup of CBD wellness products tailored to health-conscious consumers. , The retail shop ...
(Date:10/10/2019)... LOS ANGELES (PRWEB) , ... October 10, 2019 ... ... as a prolific producer of research in the field of reproductive medicine, with ... Expo, the premier conference for reproductive experts, slated for October 12-16, 2019, in ...
Breaking Medicine Technology:
(Date:10/19/2019)... Ore. (PRWEB) , ... October 18, 2019 , ... Today, ... are blind or have low vision by creating exceptional partnerships between people, guide dogs ... Alumni Reunion. Over 150 reunion attendees are coming together as a community for the ...
(Date:10/17/2019)... ... October 17, 2019 , ... Whole Foods Market, along ... for well-being transformation. It will start with an in-depth assessment by the Blue Zones ... make it a healthier and happier place to live, work, grow up, and grow ...
(Date:10/15/2019)... ... ... Genomenon® announced today at the American Society of Human Genetics Annual Meeting ... Genomic Search Engine into the SOPHiA Platform and the Alamut Suite . ... performing genomic analysis worldwide. , The SOPHiA Platform is the technology of ...
(Date:10/10/2019)... , ... October 10, 2019 , ... AltMed Florida ... (source: OMMU ), has announced the grand opening of its second MÜV™ Medical ... at 1198 Beach Blvd., Suite 4 in Jacksonville Beach. , Located at Beach Plaza ...
(Date:10/8/2019)... ... October 08, 2019 , ... What unique insights can three ... of aging and wellness in the nation? That question will be answered at ICAA ... Leadership Summit and Expo. The event will take place October 10-12, 2019, at the ...
Breaking Medicine News(10 mins):